UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ヘキソースリン酸側路およびグルタチオン代謝疾患（グルコース-6-リン酸脱水素酵素欠損症を除く） disorders of the hexose monophosphate shunt and glutathione metabolism other than glucose 6 phosphate dehydrogenase deficiency
2. 乳酸脱水素酵素欠損症 lactate dehydrogenase deficiency
3. グルコース-6-リン酸脱水素酵素欠損症の遺伝学および病態生理 genetics and pathophysiology of glucose 6 phosphate dehydrogenase deficiency
4. グルコース-6-リン酸脱水素酵素欠損症の診断とマネージメント diagnosis and management of glucose 6 phosphate dehydrogenase deficiency
5. 肝細胞障害を検出するための肝臓生化学検査 liver biochemical tests that detect injury to hepatocytes

English Journal

Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.

Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M.SourceDepartment of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland.
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2012 Nov 9. [Epub ahead of print]
BACKGROUND: This study was initiated to assess the quantitative impact of patient anthropometrics and dihydropyrimidine dehydrogenase (DPYD) mutations on the pharmacokinetics (PK) of 5-fluorouracil (5FU) and to explore limited sampling strategies of 5FU.PATIENTS AND METHODS: We included 32 patients
PMID 23139054

Phenotyping drug disposition in oncology.

Opdam FL, Gelderblom H, Guchelaar HJ.SourceDepartment of Clinical Pharmacy, University Medical Center, Leiden, The Netherlands. f.l.opdam@lumc.nl
Cancer treatment reviews.Cancer Treat Rev.2012 Oct;38(6):715-25. Epub 2012 Jan 4.
Efficacy and toxicity of anticancer agents are highly variable between patients and variation in drug disposition is thought to be an important determinant. Genetics, physiology, and environment all are underlying factors contributing to this variation. Phenotyping drug metabolizing enzymes and drug
PMID 22226243

Japanese Journal

Dihydropyrimidine dehydrogenase欠損症と診断された大腸癌の1例

鷹羽智之,森山仁,横山剛,的場周一郎,澤田壽仁
日本消化器外科学会雑誌 41(12), 2075-2080, 2008-12-01
… e4),血小板減少(grade3),粘膜障害(grade3)が出現し,内服開始日から28日後に多臓器不全で死亡した.尿中Uracil 593.0μmol/g・creに対してdihydrouracilは2.1μmol/g・creであり,dihydrouracil/uracil比0.004(基準値:0.23〜0.67)と著しく低値であること,末梢血単核球dihydropyrimidine dehydrogenase(以下,DPD)活性値が感度以下であったことからDPD欠損症と診断した.本邦においてDPD欠損症はわずか6例の報告があるのみで非常 …
NAID 110007005906

胃癌におけるOrotate Phosphoribosyl Transferase(OPRT),Dihydropyrimidine Dehydrogenase(DPD)活性と臨床病理学的因子との関連性の検討

青木太郎,小林研二,上村佳央 [他]
癌の臨床 50(10), 831-835, 2004-00-00
NAID 40007057929

3-Cyano-2,6-dihydroxy-pyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase

TATSUMI K.
J Biochem 114, 912-918, 1993
NAID 80007370078

Related Links

Dihydrouracil dehydrogenase (NADP^+^) deficiency ...

The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. Ben Fredj R, Gross E, Ben Ahmed S, Hassine H, Saguem S Pathol Biol (Paris) 2009 Sep;57(6):470-6.

Dihydrouracil dehydrogenase | definition of dihydrouracil ...

Looking for online definition of dihydrouracil dehydrogenase in the Medical Dictionary? dihydrouracil dehydrogenase explanation free. What is dihydrouracil dehydrogenase? Meaning of dihydrouracil dehydrogenase medical term

Dihydrouracil Dehydrogenase of Rat Liver

Abstract 1. The forward and reverse reactions of the enzyme commonly known as dihydrouracil dehydrogenase were found to occur in different compartments of the liver cell. 2. The hydrogenation of uracil ...